相关实验视频

Updated: Jul 14, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

通过PD1-TIGIT仿真免疫检查点开关受体增强T细胞抗瘤功效

Jingjing Zhao¹, Jiebin Dong¹, Changwen Deng²

¹Department of Cell Biology and MOE Engineering Research Center of Regenerative Medicine, School of Basic Medical Sciences, State Key Laboratory of Natural and Biomimetic Drugs, Peking University Health Science Center, Peking University, Hadian District, Beijing, China.

|October 9, 2023

概括

一种针对PD1和TIGIT的新型仿真免疫检查点开关受体 (CISR) 增强了对固体瘤的CAR T细胞治疗. 这种方法改善了T细胞的存活,增殖和抗瘤活性,为癌症免疫治疗提供了新的策略.

科学领域:

免疫学免疫学免疫学
癌症生物学癌症生物学
生物技术是生物技术.

背景情况:

卡尔-T细胞疗法对血液癌症有前途,但由于免疫抑制检查点,在固体瘤中面临局限性.
像PD1和TIGIT这样的免疫检查点阻碍了瘤微环境中的CAR T细胞抗瘤活性.

研究的目的:

开发和评估PD1-TIGIT仿真免疫检查点开关受体 (CISR),以克服CAR T细胞治疗中的检查点抑制.
通过逆转PD1/PDL1和TIGIT/CD155通路的抑制信号,增强CAR T细胞对固体瘤的疗效.

主要方法:

设计了一个结合PD1和TIGIT准CD28信号域的CISR.
评估CISR-CAR T细胞功能,包括生存,增殖,细胞因子释放和细胞毒性,在体外.
在细胞系和患者衍生异种移植固体瘤模型中评估了CISR-CAR T细胞的抗瘤疗效和瘤透.

主要成果:

与常规CAR T细胞相比,CISR-CAR T细胞在体外表现出增强的生存,增殖,细胞因子释放和细胞毒性.
在不同的固体瘤模型中,CISR-CAR T细胞在体内表现出强大的透和显著的抗瘤活性.
设计的CISR有效地逆转了抑制检查点信号,促进了T细胞的抗瘤反应.

结论:

PD1-TIGIT CISR策略显著提高了CAR T细胞在固体瘤中的抗瘤功效.
CISR代表了一种有希望的方法来克服免疫抑制,并改善用于癌症治疗的基于T细胞的免疫疗法.

关键词:

癌症免疫疗法癌症免疫疗法这就是PD1 PD1.这是一个紧张的紧张.仿制性抗原受体T T的受体.免疫检查点检查点

更多相关视频

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.